Author:
Dai Liang,Wu Ya-Ya,Sun Yan,Yu Rong,Yan Wan-Pu,Yang Yong-Bo,Cheng Hong,Gao Yi-Mei,Zhang Bin,Chen Ke-Neng
Abstract
Abstract
Background
Definitive chemoradiotherapy is recommended as the primary treatment for cervical esophageal carcinoma (CEC). However, local control rates remain unsatisfactory for some patients. Therefore, in this study, we introduced a new treatment paradigm for individuals with CEC, customizing the choice between subsequent local treatments based on their response to induction chemotherapy and immunotherapy.
Patients and Methods
Induction treatment comprised two to four cycles of chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitors. Patients achieving complete response (CR) or near CR after induction treatment underwent definitive chemoradiotherapy (dCRT), while those not achieving CR or near CR underwent surgical resection.
Results
Among the 40 eligible patients, 14 (35.0%) achieved a CR or near CR after induction treatment. Of the ten patients achieving a CR or near CR, one developed an esophageal fistula after dCRT (10.0%). Among the eight non-CR or non-near CR patients receiving chemoradiotherapy, six developed esophageal fistula (75.0%). Among the 26 patients who did not achieve CR or near CR after induction treatment, the 1-year cancer specific survival (CSS) rates were 93.3% [95% confidence interval (CI) 0.815–1%] for the 18 patients in the surgery group, and 71.4% (95% CI 0.447–1%) for the 8 patients in the chemoradiotherapy group (p = 0.027). The overall laryngeal preservation rate was 85.0% (34/40), with a functional laryngeal preservation rate of 77.5% (31/40).
Conclusion
The approach consisting of combined immunotherapy and chemotherapy successfully identified patients who were responding well to induction treatment and who were sensitive to radiotherapy, for chemoradiotherapy; thus, improving laryngeal preservation rates. In addition, it also identified patients with poor responses to induction treatment and radiotherapy, for timely surgery; hence, reducing radiotherapy complications and enhancing survival.
Funder
the Beijing Municipal Administration of Hospitals Special Fund for Digestive System Multidisciplinary Synergic Development
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Buckstein M, Liu J. Cervical esophageal cancers: challenges and opportunities. Curr Oncol Rep. 2019;21:46.
2. Nikbakhsh N, Saidi F, Fahimi H. A new technical approach to cancers of the cervical esophagus. Arch Iran Med. 2012;15:298–302.
3. NCCN. Esophageal and Esophagogastric Junction Cancers, Version 2.2023[DB/OL]
4. Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2015;116(2):257–61.
5. Zhao D, Zheng B, Xiao S, et al. Mapping of regional failures after definitive radiotherapy in patients with locally advanced cervical esophageal carcinoma. Cancer Manag Res. 2020;12:5293–9.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献